OBJECTIVES: Incidence rates (IRs) of Staphylococcus aureus bacteraemia (SAB) are known to be higher in HIV-infected individuals than in the general population, but have not been assessed in the era of highly active antiretroviral therapy. METHODS: From 1 January 1995 to 31 December 2007, all Danish HIV-infected individuals (n=4871) and population controls (n=92 116) matched on age and sex were enrolled in a cohort and all cases of SAB were registered. IRs and risk factors were estimated using time-updated Poisson regression analysis. RESULTS: We identified 329 cases of SAB in 284 individuals, of whom 132 individuals were infected with HIV and 152 were not [crude IR ratio (IRR) 24.2; 95% confidence interval (CI) 19.5-30.0, for HIV-infected vs. non-HIV-infected individuals]. Over time, IR declined for HIV-infected individuals (IRR 0.40). Injecting drug users (IDUs) had the highest incidence and the smallest decline in IR, while men who have sex with men (MSM) had the largest decline over time. Among HIV-infected individuals, a latest CD4 count <100 cells/μL was the strongest independent predictor of SAB (IRR 10.2). Additionally, HIV transmission group was associated with risk of SAB. MSM were more likely to have hospital-acquired SAB, a low CD4 cell count and AIDS at the time of HIV acquisition compared with IDUs. CONCLUSIONS: We found that the incidence of SAB among HIV-infected individuals declined during the study period, but remained higher than that among HIV-uninfected individuals. There was an unevenly distributed burden of SAB among HIV transmission groups (IDU>MSM). Low CD4 cell count and IDU were strong predictors of SAB among HIV-infected individuals.
OBJECTIVES: Incidence rates (IRs) of Staphylococcus aureus bacteraemia (SAB) are known to be higher in HIV-infected individuals than in the general population, but have not been assessed in the era of highly active antiretroviral therapy. METHODS: From 1 January 1995 to 31 December 2007, all Danish HIV-infected individuals (n=4871) and population controls (n=92 116) matched on age and sex were enrolled in a cohort and all cases of SAB were registered. IRs and risk factors were estimated using time-updated Poisson regression analysis. RESULTS: We identified 329 cases of SAB in 284 individuals, of whom 132 individuals were infected with HIV and 152 were not [crude IR ratio (IRR) 24.2; 95% confidence interval (CI) 19.5-30.0, for HIV-infected vs. non-HIV-infected individuals]. Over time, IR declined for HIV-infected individuals (IRR 0.40). Injecting drug users (IDUs) had the highest incidence and the smallest decline in IR, while men who have sex with men (MSM) had the largest decline over time. Among HIV-infected individuals, a latest CD4 count <100 cells/μL was the strongest independent predictor of SAB (IRR 10.2). Additionally, HIV transmission group was associated with risk of SAB. MSM were more likely to have hospital-acquired SAB, a low CD4 cell count and AIDS at the time of HIV acquisition compared with IDUs. CONCLUSIONS: We found that the incidence of SAB among HIV-infected individuals declined during the study period, but remained higher than that among HIV-uninfected individuals. There was an unevenly distributed burden of SAB among HIV transmission groups (IDU>MSM). Low CD4 cell count and IDU were strong predictors of SAB among HIV-infected individuals.
Authors: Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell Journal: Clin Microbiol Rev Date: 2012-04 Impact factor: 26.132
Authors: Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler Journal: Clin Microbiol Rev Date: 2015-07 Impact factor: 26.132
Authors: Joya-Rita Hindy; Juan A Quintero-Martinez; Alexander T Lee; Christopher G Scott; Danielle J Gerberi; Maryam Mahmood; Daniel C DeSimone; Larry M Baddour Journal: Cureus Date: 2022-05-29
Authors: Bianca Stammler Jaliff; Jenny Dahl-Knudsen; Andreas Petersen; Robert Skov; Thomas Benfield Journal: BMJ Open Date: 2014-04-23 Impact factor: 2.692
Authors: Lise H Nielsen; Søren Jensen-Fangel; Thomas Benfield; Robert Skov; Bente Jespersen; Anders R Larsen; Lars Østergaard; Henrik Støvring; Henrik C Schønheyder; Ole S Søgaard Journal: BMC Infect Dis Date: 2015-01-08 Impact factor: 3.090
Authors: Cynthia Regina Pedrosa Soares; Celso Rodrigues de Lira; Maximiliano Alexandre H Cunha; Valter Romão de Souza Junior; Fábio Lopes de Melo; Paulo Sergio Ramos de Araújo; Maria Amélia Vieira Maciel Journal: BMC Res Notes Date: 2018-11-06
Authors: Thibaut Davy-Mendez; Sonia Napravnik; Brenna C Hogan; Keri N Althoff; Kelly A Gebo; Richard D Moore; Michael A Horberg; Michael J Silverberg; M John Gill; Heidi M Crane; Vincent C Marconi; Ronald J Bosch; Jonathan A Colasanti; Timothy R Sterling; W Christopher Mathews; Angel M Mayor; Ni Gusti Ayu Nanditha; Kate Buchacz; Jun Li; Peter F Rebeiro; Jennifer E Thorne; Ank Nijhawan; David van Duin; David A Wohl; Joseph J Eron; Stephen A Berry Journal: J Infect Dis Date: 2021-06-15 Impact factor: 5.226